Phillips Medisize, a Molex subsidiary CDMO that focuses on inhalation products and other medical and diagnostic products, is expanding its manufacturing footprint in the U.K.
Under the newly disclosed investment, Phillips Medisize will finish out the footprint of its Chippenham site that, together the company’s Cambridge facility, will boost its global inhalation center of excellence and expand capacity to support expected growth in the sector, the company said in a press release.
The 634,670-square-foot site that sits on 3.41 acres will support Phillips Medicine’s ambition to grow drug-device combination product formulation development for early and late-phase clinical trial supplies production.
Financial terms of the deal weren’t disclosed.
“With our inhalation revenue projected to grow substantially over the next five years, securing this full site ensures we have the dedicated talent, laboratories and cleanroom capacity required to support pharmaceutical companies from early-stage feasibility all the way through commercial scale-up,” Charlie Schumacher, vice president of inhalation therapies at Phillips Medisize, said in a statement. “Since the Vectura acquisition, we are tracking ahead of schedule on our growth model and are confident in our trajectory.”
Phillips Medisize acquired Vectura through Molex in late 2024 for an undisclosed price. The developer and maker of inhaled medicines and devices like asthma inhalers, nebulizers and dry-powder inhalers was previously purchased for $1.2 billion in 2021 by Philip Morris International.
Molex is a wholly-owned subsidiary of Koch (formerly Koch industries), which acquired the Illinois maker of electronic, electrical, and fiber optic connectivity systems in 2013 for an estimated $7.2 billion.